← Leaderboards
Stanley R Hoffman
Medical University Of South Carolina
$3,862,547
Attributed
$3,862,547
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $559.5K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,862,547 · 9
By mechanism
R01$1,672,526 · 2
R41$1,428,740 · 5
R21$761,281 · 2
Top collaborators
No co-investigators on record.
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Richard M. Silver$2,926,564
- Galina S Bogatkevich$1,137,408
- Lucille London$861,179
Others in their field
Top investigators on “Collagen”
- Gary K Owens · University Of Virginia$22,073,978
- Billy Gerald Hudson · Vanderbilt University Medical Center$19,036,330
- Ravinder R Regatte · New York University School Of Medicine$18,437,784
- Brendan Hl Lee · Baylor College Of Medicine$16,945,312
- David E Harrison · Jackson Laboratory$16,731,987
- J. Edwin Blalock · University Of Alabama At Birmingham$16,139,060
Research focus
CollagenFibrosisLeadPeptidesTherapeutic TargetCellsBleomycinSclerodermaFutureEnzymesAffectIn VivoAbsorptionMetabolismTissuesScaffoldBiological ModelsPulmonary FibrosisTertiary Protein StructureApoptosisFibroblastsMouse ModelDoseCaveolin 1
Grant awards (15)
Novel Therapeutic for Kidney Failure: A Modified, Water-Soluble Orally-Active Caveolin-1 Scaffolding Domain Peptide with Improved Characteristics for Drug Development$337,740
R41 · FY2024 · DK · contact PI
Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development$6,500
R41 · FY2024 · HL · contact PI
Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development$299,972
R41 · FY2023 · HL · contact PI
Novel Therapeutics for Interstitial Lung Disease: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development$299,930
R41 · FY2022 · HL · contact PI
Development of Modified Caveolin-1 Scaffolding Domain Peptides with Improved Pharmacological Properties as Therapeutic Agents for Scleroderma Skin Disease$259,601
R41 · FY2022 · AR · contact PI
Enhancement of the Beneficial Effects of Mesenchymal Stem Cell (MSC) Treatment by the Caveolin-1 Scaffolding Domain Peptide (CSD)$224,997
R41 · FY2018 · HL · contact PI
Curcumin Treatment of Lung Fibrosis: Improved Delivery and Target Cells$182,531
R21 · FY2011 · AT · contact PI
Curcumin Treatment of Lung Fibrosis: Improved Delivery and Target Cells$221,250
R21 · FY2010 · AT · contact PI
PKCepsilon-Related Proteins in Lung Fibrosis$356,423
R01 · FY2006 · HL · contact PI
PKCepsilon-Related Proteins in Lung Fibrosis$365,000
R01 · FY2005 · HL
PKCepsilon-Related Proteins in Lung Fibrosis$365,000
R01 · FY2004 · HL
PKCepsilon-Related Proteins in Lung Fibrosis$365,000
R01 · FY2003 · HL
R21 Project: Curcumin Treatment of Fibrosis$178,750
R21 · FY2002 · AT
Curcumin Treatment of Fibrosis$178,750
R21 · FY2001 · AT
CELL/CELL AND MATRIX INTERACTIONS IN HEART MORPHOGENESIS$221,103
R01 · FY2000 · HL